BCL2 and melanoma: The strong activation of MITF/Bcl‐2 pathway is one of reasons that lead to acquired resistance of MEK inhibitor for NRAS‐mutant melanoma, and anti‐Bcl‐2 (ABT‐199) annihilated the acquired resistance and restored the sensitivity of NRAS‐mutant melanoma cells to MEK inhibitor [364].